The prevalence of human papillomavirus type 58 in chinese patients with cervical carcinoma and its influence on survival

Walayat Shah, Chen Hongwei, Zheng Jin, Dong Lifang, Yu Jun, Wang Yili

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To assess the prevalence of human papillomavirus (HPV) type-specific infections and its influence on prognosis and survival rate of cervical cancer patients treated with radiotherapy alone or in combination with chemotherapy or hyperthermotherapy or both. During 1993 and 1994, 120 patients with cervical cancer were consecutively assigned into four therapeutic modalities. One hundred and eight formalin-fixed and paraffin-embedded tissue samples available at the time of this study were subjected to DNA extraction. The DNA was analysed for the presence of HPV and HPV type-specific infections with polymerase chain reaction. The experimental data were co-analysed with the follow-up data to evaluate prognosis and survival in relation to the HPV infection and treatment. All samples were found to be positive for HPV; 32.40% (95% confidence interval 23.72-42.09) of samples were HPV 16 single positive, 16.67% (95% confidence interval 10.19-25.06) were HPV 58 single positive, 34.26% (95% confidence interval 25.4-44.01) were HPV 16/58 double positive and 16.67% (95% confidence interval 10.19-25.06) were positive for other HPV types. The 5-year survival rates were 88.89, 80.0, 67.57 and 61.11% in patients with HPV 58 single positive, HPV 16 single positive, HPV 16/58 double positive, and other HPV types, respectively (P = 0.18), irrespective of the treatment modalities. Univariate Cox regression analysis results showed that compared with the HPV 16 single positive group, the relative risk of death was high in the HPV 16/58 double positive group (hazard ratio 1.81, 95% confidence interval 0.71-4.60) and the other HPV types group (hazard ratio 2.09, 95% confidence interval 0.73-5.96), whereas it was lower in the HPV 58 single positive group (hazard ratio 0.53, 95% confidence interval 0.11-2.56), but this was not statistically significant (P = 0.43). All results remained statistically non-significant after adjustment for age and tumour stage with multivariate Cox regression. No apparent differences were observed in the survival rates among the four groups with regard to the treatment protocols. No effect was seen of either treatment protocols or HPV type on survival, except for a slightly high survival in HPV 58 single-infected patients, which was statistically non-significant.
LanguageEnglish
Pages768-774
Number of pages6
JournalClinical Oncology
Volume21
Issue number10
DOIs
Publication statusPublished - 2009

Fingerprint

Carcinoma
Survival
Human papillomavirus 16
Confidence Intervals
Papillomavirus Infections
Survival Rate
Clinical Protocols
Uterine Cervical Neoplasms
Time and Motion Studies
DNA
Combination Drug Therapy
Paraffin
Formaldehyde
Radiotherapy
Therapeutics
Regression Analysis
Polymerase Chain Reaction

Keywords

  • cervical carcinoma
  • chemoradiotherapy
  • human papillomavirus
  • prevalence
  • radiotherapy
  • survival

Cite this

Shah, Walayat ; Hongwei, Chen ; Jin, Zheng ; Lifang, Dong ; Jun, Yu ; Yili, Wang. / The prevalence of human papillomavirus type 58 in chinese patients with cervical carcinoma and its influence on survival. In: Clinical Oncology. 2009 ; Vol. 21, No. 10. pp. 768-774.
@article{5b81aa325db943be9be8d06d255558b2,
title = "The prevalence of human papillomavirus type 58 in chinese patients with cervical carcinoma and its influence on survival",
abstract = "To assess the prevalence of human papillomavirus (HPV) type-specific infections and its influence on prognosis and survival rate of cervical cancer patients treated with radiotherapy alone or in combination with chemotherapy or hyperthermotherapy or both. During 1993 and 1994, 120 patients with cervical cancer were consecutively assigned into four therapeutic modalities. One hundred and eight formalin-fixed and paraffin-embedded tissue samples available at the time of this study were subjected to DNA extraction. The DNA was analysed for the presence of HPV and HPV type-specific infections with polymerase chain reaction. The experimental data were co-analysed with the follow-up data to evaluate prognosis and survival in relation to the HPV infection and treatment. All samples were found to be positive for HPV; 32.40{\%} (95{\%} confidence interval 23.72-42.09) of samples were HPV 16 single positive, 16.67{\%} (95{\%} confidence interval 10.19-25.06) were HPV 58 single positive, 34.26{\%} (95{\%} confidence interval 25.4-44.01) were HPV 16/58 double positive and 16.67{\%} (95{\%} confidence interval 10.19-25.06) were positive for other HPV types. The 5-year survival rates were 88.89, 80.0, 67.57 and 61.11{\%} in patients with HPV 58 single positive, HPV 16 single positive, HPV 16/58 double positive, and other HPV types, respectively (P = 0.18), irrespective of the treatment modalities. Univariate Cox regression analysis results showed that compared with the HPV 16 single positive group, the relative risk of death was high in the HPV 16/58 double positive group (hazard ratio 1.81, 95{\%} confidence interval 0.71-4.60) and the other HPV types group (hazard ratio 2.09, 95{\%} confidence interval 0.73-5.96), whereas it was lower in the HPV 58 single positive group (hazard ratio 0.53, 95{\%} confidence interval 0.11-2.56), but this was not statistically significant (P = 0.43). All results remained statistically non-significant after adjustment for age and tumour stage with multivariate Cox regression. No apparent differences were observed in the survival rates among the four groups with regard to the treatment protocols. No effect was seen of either treatment protocols or HPV type on survival, except for a slightly high survival in HPV 58 single-infected patients, which was statistically non-significant.",
keywords = "cervical carcinoma, chemoradiotherapy, human papillomavirus, prevalence, radiotherapy, survival",
author = "Walayat Shah and Chen Hongwei and Zheng Jin and Dong Lifang and Yu Jun and Wang Yili",
note = "PMID: 19875274",
year = "2009",
doi = "10.1016/j.clon.2009.09.003",
language = "English",
volume = "21",
pages = "768--774",
journal = "Clinical Oncology",
issn = "0936-6555",
number = "10",

}

The prevalence of human papillomavirus type 58 in chinese patients with cervical carcinoma and its influence on survival. / Shah, Walayat; Hongwei, Chen; Jin, Zheng; Lifang, Dong; Jun, Yu; Yili, Wang.

In: Clinical Oncology, Vol. 21, No. 10, 2009, p. 768-774.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The prevalence of human papillomavirus type 58 in chinese patients with cervical carcinoma and its influence on survival

AU - Shah, Walayat

AU - Hongwei, Chen

AU - Jin, Zheng

AU - Lifang, Dong

AU - Jun, Yu

AU - Yili, Wang

N1 - PMID: 19875274

PY - 2009

Y1 - 2009

N2 - To assess the prevalence of human papillomavirus (HPV) type-specific infections and its influence on prognosis and survival rate of cervical cancer patients treated with radiotherapy alone or in combination with chemotherapy or hyperthermotherapy or both. During 1993 and 1994, 120 patients with cervical cancer were consecutively assigned into four therapeutic modalities. One hundred and eight formalin-fixed and paraffin-embedded tissue samples available at the time of this study were subjected to DNA extraction. The DNA was analysed for the presence of HPV and HPV type-specific infections with polymerase chain reaction. The experimental data were co-analysed with the follow-up data to evaluate prognosis and survival in relation to the HPV infection and treatment. All samples were found to be positive for HPV; 32.40% (95% confidence interval 23.72-42.09) of samples were HPV 16 single positive, 16.67% (95% confidence interval 10.19-25.06) were HPV 58 single positive, 34.26% (95% confidence interval 25.4-44.01) were HPV 16/58 double positive and 16.67% (95% confidence interval 10.19-25.06) were positive for other HPV types. The 5-year survival rates were 88.89, 80.0, 67.57 and 61.11% in patients with HPV 58 single positive, HPV 16 single positive, HPV 16/58 double positive, and other HPV types, respectively (P = 0.18), irrespective of the treatment modalities. Univariate Cox regression analysis results showed that compared with the HPV 16 single positive group, the relative risk of death was high in the HPV 16/58 double positive group (hazard ratio 1.81, 95% confidence interval 0.71-4.60) and the other HPV types group (hazard ratio 2.09, 95% confidence interval 0.73-5.96), whereas it was lower in the HPV 58 single positive group (hazard ratio 0.53, 95% confidence interval 0.11-2.56), but this was not statistically significant (P = 0.43). All results remained statistically non-significant after adjustment for age and tumour stage with multivariate Cox regression. No apparent differences were observed in the survival rates among the four groups with regard to the treatment protocols. No effect was seen of either treatment protocols or HPV type on survival, except for a slightly high survival in HPV 58 single-infected patients, which was statistically non-significant.

AB - To assess the prevalence of human papillomavirus (HPV) type-specific infections and its influence on prognosis and survival rate of cervical cancer patients treated with radiotherapy alone or in combination with chemotherapy or hyperthermotherapy or both. During 1993 and 1994, 120 patients with cervical cancer were consecutively assigned into four therapeutic modalities. One hundred and eight formalin-fixed and paraffin-embedded tissue samples available at the time of this study were subjected to DNA extraction. The DNA was analysed for the presence of HPV and HPV type-specific infections with polymerase chain reaction. The experimental data were co-analysed with the follow-up data to evaluate prognosis and survival in relation to the HPV infection and treatment. All samples were found to be positive for HPV; 32.40% (95% confidence interval 23.72-42.09) of samples were HPV 16 single positive, 16.67% (95% confidence interval 10.19-25.06) were HPV 58 single positive, 34.26% (95% confidence interval 25.4-44.01) were HPV 16/58 double positive and 16.67% (95% confidence interval 10.19-25.06) were positive for other HPV types. The 5-year survival rates were 88.89, 80.0, 67.57 and 61.11% in patients with HPV 58 single positive, HPV 16 single positive, HPV 16/58 double positive, and other HPV types, respectively (P = 0.18), irrespective of the treatment modalities. Univariate Cox regression analysis results showed that compared with the HPV 16 single positive group, the relative risk of death was high in the HPV 16/58 double positive group (hazard ratio 1.81, 95% confidence interval 0.71-4.60) and the other HPV types group (hazard ratio 2.09, 95% confidence interval 0.73-5.96), whereas it was lower in the HPV 58 single positive group (hazard ratio 0.53, 95% confidence interval 0.11-2.56), but this was not statistically significant (P = 0.43). All results remained statistically non-significant after adjustment for age and tumour stage with multivariate Cox regression. No apparent differences were observed in the survival rates among the four groups with regard to the treatment protocols. No effect was seen of either treatment protocols or HPV type on survival, except for a slightly high survival in HPV 58 single-infected patients, which was statistically non-significant.

KW - cervical carcinoma

KW - chemoradiotherapy

KW - human papillomavirus

KW - prevalence

KW - radiotherapy

KW - survival

UR - http://dx.doi.org/10.1016/j.clon.2009.09.003

U2 - 10.1016/j.clon.2009.09.003

DO - 10.1016/j.clon.2009.09.003

M3 - Article

VL - 21

SP - 768

EP - 774

JO - Clinical Oncology

T2 - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 10

ER -